Genmab Analyst Price Targets

Wall Street analyst price targets and consensus rating for Genmab (GMAB).

Price Target Range — 13 Quarters

Analyst Consensus — 13 Analysts

13Buy

Consensus RatingBuy# Analysts13Avg. Consensus PT$48Upside to Avg. PT-16.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 30, 2026	Morgan Stanley	Judah Frommer	PT Raise	Equal-Weight	$42→$57
Oct 30, 2026	Guggenheim	Michael Schmidt	PT Raise	Buy	$58→$80
Oct 29, 2026	Truist Securities	Gregory Renza	PT Raise	Buy	$45→$67
Oct 29, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$50→$70
Oct 26, 2026	TD Cowen	Yaron Werber	PT Raise	Buy	$43→$52
Oct 26, 2026	JP Morgan	James Gordon	Upgrade	Neutral→Overweight	—
Oct 7, 2026	Truist Securities	Asthika Goonewardene	PT Raise	Buy	$40→$45
Oct 7, 2026	Guggenheim	Michael Schmidt	PT Raise	Buy	$54→$58
Oct 7, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$40→$50
Oct 5, 2026	Guggenheim	Michael Schmidt	PT Raise	Buy	$45→$54
Sep 14, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$40
Aug 7, 2026	Guggenheim	Michael Schmidt	PT Raise	Buy	$40→$42
Jul 22, 2026	TD Cowen	Yaron Werber	Upgrade	Hold→Buy	$32→$43
Jul 2, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$38→$40
Jun 23, 2026	HC Wainwright & Co.	Raghuram Selvaraju	Maintained	Buy	$38
Apr 30, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Cut	Buy	$40→$38
Mar 27, 2026	Wolfe Research	Kalpit Patel	Initiate	Outperform	$32
Mar 2, 2026	Wells Fargo	Eva Fortea Verdejo	Initiate	Overweight	$40
Feb 23, 2026	Guggenheim	Michael Schmidt	PT Cut	Buy	$45→$40
Feb 18, 2026	HC Wainwright & Co.	Raghuram Selvaraju	PT Raise	Buy	$39→$40